<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FERRIPROX- deferiprone tablet, film coated </strong><br>ApoPharma USA, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use FERRIPROX safely and effectively. See full prescribing information for FERRIPROX.<br><br>FERRIPROX<span class="Sup">®</span> (deferiprone) tablets, for oral use<br>Initial U.S. Approval: 2011</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span></span><span class="Bold">/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span> </span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Bold">
<li><h1 class="Warning">Ferriprox can cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> that can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> may precede the development of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. (5.1)</h1></li>
<li><h1 class="Warning"> Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor the ANC weekly on therapy. (5.1)</h1></li>
<li><h1 class="Warning">Interrupt Ferriprox if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops and monitor the ANC more frequently. (5.1)</h1></li>
<li><h1 class="Warning">Advise patients taking Ferriprox to report immediately any symptoms indicative of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (5.1)</h1></li>
</ul>
</div></div>
<div><div></div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span></span><span class="Bold">/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span> </span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Bold">
<li><h1 class="Warning">Ferriprox can cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> that can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> may precede the development of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. (5.1)</h1></li>
<li><h1 class="Warning"> Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor the ANC weekly on therapy. (5.1)</h1></li>
<li><h1 class="Warning">Interrupt Ferriprox if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops and monitor the ANC more frequently. (5.1)</h1></li>
<li><h1 class="Warning">Advise patients taking Ferriprox to report immediately any symptoms indicative of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (5.1)</h1></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FERRIPROX<span class="Sup">®</span> (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> due to <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> syndromes when current chelation therapy is inadequate.<a href="#INDICATIONS_AND_USAGE"> (1)</a> </p>
<p class="Highlighta">Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival. <a href="#INDICATIONS_AND_USAGE">(1)</a> </p>
<p class="Highlighta">Limitation of Use </p>
<ul><li>Safety and effectiveness have not been established for the treatment of transfusional <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> in patients with other chronic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span>. <a href="#INDICATIONS_AND_USAGE">(1)</a><span class="Italics"></span><a href="#INDICATIONS_AND_USAGE"></a>
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>25 mg/kg to 33 mg/kg body weight, orally, three times per day, for a total daily dose of 75 mg/kg to 99 mg/kg body weight. <a href="#DOSAGE_AND_ADMINISTRATION">(2)</a>
</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>500 mg film-coated tablets with a functional score. <a href="#DOSAGE_FORMS_AND_STRENGTHS">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to deferiprone or to any of the excipients in the formulation. <a href="#CONTRAINDICATIONS">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>If <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs while on Ferriprox, interrupt therapy and monitor the ANC more frequently. (5.1)</li>
<li>Ferriprox can cause fetal harm. Women should be advised of the potential hazard to the fetus and to avoid pregnancy while on this drug. (5.2)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul><li>The most common adverse reactions are (incidence ≥ 5%) <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">chromaturia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. (<a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943">5.1</a>, <a href="#ADVERSE_REACTIONS">6</a>)<p class="Highlighta"> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at: </span><span class="Bold">Telephone: 1-866-949-0995</span> </p>
<p class="Highlighta"><span class="Bold">Email: </span><span class="Bold Underline"><a href="http://mailto:medicalsafety@apopharma.com">medicalsafety@apopharma.com</a></span><span class="Bold"> or FDA at 1-800-FDA-1088 or </span><span class="Bold"></span><span class="Bold Underline"></span><span class="Bold Underline"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"> </p>
<ul><li><p class="Highlighta">Avoid concomitant use with other drugs known to be associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; however, if this is not possible, closely monitor the absolute neutrophil count. <a href="#_ae1f7d66-1500-0844-b15d-fcb050958142">(7.1)</a> </p></li></ul>
<ul><li><p class="Highlighta">Allow at least a 4-hour interval between Ferriprox and mineral supplements, and antacids that contain polyvalent cations (e.g., iron, aluminum, and zinc). <a href="#_1b7d6643-cbc3-d8e9-c5ca-20da7cccc058">(7.3)</a> </p></li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Safety and efficacy of Ferriprox has not been evaluated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#_30640f47-25f8-9438-a634-57dad153ba13">8.7</a>)</li>
<li>Nursing mothers: Discontinue the use of Ferriprox or discontinue nursing. (<a href="#NURSING_MOTHERS">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Interactions with Foods, Vitamins and Antacids</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a></h2>
<h2><a href="#section-5.2" class="toc"> 5.2 Embryofetal Toxicity </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc"> 7.1 Drugs Associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </a></h2>
<h2><a href="#section-7.2" class="toc"> 7.2 UDP-Glucuronosyltransferases (UGTs) </a></h2>
<h2><a href="#section-7.3" class="toc"> 7.3 Polyvalent Cations </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">
      8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">
      8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Warning">
<a name="BOXED_WARNING"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span></h1>
<ul>
<li><p class="First"><span class="Bold">Ferriprox can cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> that can lead to serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> may precede the development of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. </span><span class="Bold Italics">[see<a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943"> Warnings and Precautions (5.1)</a>]</span></p></li>
<li><p class="First"><span class="Bold">Measure the absolute neutrophil count (ANC) before starting Ferriprox therapy and monitor the ANC weekly on therapy. Interrupt Ferriprox therapy if <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops. </span><span class="Bold Italics">[see<a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943"> Warnings and Precautions (5.1)</a></span><span class="Bold Italics">]</span></p></li>
<li><p class="First"><span class="Bold"></span><span class="Bold"> Interrupt Ferriprox if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, and monitor the ANC more frequently. </span><span class="Bold Italics">[see<a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943"> Warnings and Precautions (5.1)</a></span><span class="Bold Italics">]</span><span class="Bold"></span></p></li>
<li><p class="First"><span class="Bold">Advise patients taking Ferriprox to report immediately any symptoms indicative of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </span><span class="Bold Italics">[see <a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943">Warnings and Precautions (5.1)</a>]</span></p></li>
</ul>
<p class="First"><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS_AND_USAGE"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">FERRIPROX<span class="Sup">®</span> (deferiprone) is indicated for the treatment of patients with transfusional <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> due to <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> syndromes when current chelation therapy is inadequate.</p>
<p>Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival <span class="Italics">[see <a href="#CLINICAL_STUDIES">Clinical Studies (14)</a>]</span>.</p>
<p>Limitation of Use:</p>
<ul><li>Safety and effectiveness have not been established for the treatment of transfusional <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> in patients with other chronic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended initial dose of Ferriprox is 25 mg/kg, orally, three times per day for a total of 75 mg/kg/day. The maximum dose is 33 mg/kg, three times per day for a total of 99 mg/kg/day.</p>
<p>Dose adjustments up to 33 mg/kg, orally, three times per day should be tailored to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). The maximum recommended total daily dose is 99 mg/kg per day. The dose should be rounded by the prescriber to the nearest 250 mg (half-tablet).</p>
<table frame="border" width="80%">
<caption><span>Table 1a: Tablet requirement to achieve a 25 mg/kg (rounded to the nearest half-tablet) dose level for administration three times a day.</span></caption>
<tbody class="Headless" align="center">
<tr class="First">
<th>Body Weight (kg)</th>
<th>Dose (mg)</th>
<th>Number of tablets</th>
</tr>
<tr>
<td colspan="1">20</td>
<td colspan="1">500</td>
<td colspan="1">1</td>
</tr>
<tr>
<td colspan="1">30</td>
<td colspan="1">750</td>
<td colspan="1">1.5</td>
</tr>
<tr>
<td colspan="1">40</td>
<td colspan="1">1000</td>
<td colspan="1">2</td>
</tr>
<tr>
<td colspan="1">50</td>
<td colspan="1">1250</td>
<td colspan="1">2.5</td>
</tr>
<tr>
<td colspan="1">60</td>
<td colspan="1">1500</td>
<td colspan="1">3</td>
</tr>
<tr>
<td colspan="1">70</td>
<td colspan="1">1750</td>
<td colspan="1">3.5</td>
</tr>
<tr>
<td colspan="1">80</td>
<td colspan="1">2000</td>
<td colspan="1">4</td>
</tr>
<tr class="Last">
<td colspan="1">90</td>
<td colspan="1">2250</td>
<td colspan="1">4.5</td>
</tr>
</tbody>
</table>
<table frame="border" width="80%">
<caption><span>Table 1b: Tablet requirement to achieve 33 mg/kg (rounded to the nearest half-tablet) dose level for administration three times a day.</span></caption>
<tbody class="Headless" align="center">
<tr class="First">
<th colspan="1" rowspan="1">Body Weight (kg)</th>
<th colspan="1" rowspan="1">Dose (mg)</th>
<th colspan="1" rowspan="1">Number of tablets</th>
</tr>
<tr>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1">660</td>
<td colspan="1" rowspan="1">1.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1">990</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">40</td>
<td colspan="1" rowspan="1">1320</td>
<td colspan="1" rowspan="1">2.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">50</td>
<td colspan="1" rowspan="1">1650</td>
<td colspan="1" rowspan="1">3.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">1980</td>
<td colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">70</td>
<td colspan="1" rowspan="1">2310</td>
<td colspan="1" rowspan="1">4.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">80</td>
<td colspan="1" rowspan="1">2640</td>
<td colspan="1" rowspan="1">5.5</td>
</tr>
<tr class="Last">
<td colspan="1" rowspan="1">90</td>
<td colspan="1" rowspan="1">2970</td>
<td colspan="1" rowspan="1">6</td>
</tr>
</tbody>
</table>
<p>Monitor serum ferritin concentration every two to three months to assess the effects of Ferriprox on body iron stores. Dose adjustments should be tailored to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). If the serum ferritin <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> consistently below 500 mcg/L, consider temporarily interrupting Ferriprox therapy.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="_e50157d0-ebcc-6cb0-b3f4-6dfd5660a172"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Interactions with Foods, Vitamins and Antacids</h2>
<p class="First">Allow at least a 4-hour interval between Ferriprox and other medications or supplements containing polyvalent cations such as iron, aluminum, and zinc <span class="Italics">[see <a href="#_1b7d6643-cbc3-d8e9-c5ca-20da7cccc058">Drug Interactions (7.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">500 mg film-coated tablets with a functional score.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul><li>Ferriprox is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to deferiprone or to any of the excipients in the formulation. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; and <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span> with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> <span class="Italics">[see <a href="#_19DEE7E9-1F0A-96B7-E2F6-AEF762FA3874"> Adverse Reactions (6.2)</a>]</span>.</li></ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS_AND_PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="_DF7D5737-989A-B85C-5147-FAB6EA015943"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Fatal <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> can occur with Ferriprox use. Ferriprox can also cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, which may foreshadow <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Measure the absolute neutrophil count (ANC) before starting Ferriprox therapy and monitor the ANC weekly on therapy.</p>
<p>Interrupt Ferriprox therapy if <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops (ANC &lt; 1.5 x 10<span class="Sup">9</span>/L).</p>
<p>Interrupt Ferriprox if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, and monitor the ANC more frequently.</p>
<p>Advise patients taking Ferriprox to immediately interrupt therapy and report to their physician if they experience any symptoms indicative of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>In pooled clinical trials, the incidence of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> was 1.7% of patients. The mechanism of Ferriprox-associated <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> is unknown. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> usually resolve upon discontinuation of Ferriprox, but there have been reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Implement a plan to monitor for and to manage <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> prior to initiating Ferriprox treatment.</p>
<p><span class="Bold">For <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC &lt; 1.5 x 10<span class="Sup">9</span>/L and &gt; 0.5 x 10<span class="Sup">9</span>/L):</span></p>
<p>Instruct the patient to immediately discontinue Ferriprox and all other medications with a potential to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>Obtain a complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count daily until recovery (ANC ≥ 1.5 x 10<span class="Sup">9</span>/L).<span class="Bold"></span></p>
<p><span class="Bold">For <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (ANC &lt; 0.5 x 10<span class="Sup">9</span>/L):</span></p>
<p><span class="Bold"></span>Consider hospitalization and other management as clinically appropriate.</p>
<p>Do not resume Ferriprox in patients who have developed <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> unless potential benefits outweigh potential risks. Do not rechallenge patients who develop <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> with Ferriprox unless potential benefits outweigh potential risks.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_EF6548E5-425A-A1EB-1D85-7714CA42FE86"></a><a name="section-5.2"></a><p></p>
<h2> 5.2 Embryofetal Toxicity </h2>
<p class="First">Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman. In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and malformations at doses lower than equivalent human clinical doses. If Ferriprox is used during pregnancy or if the patient becomes pregnant while taking Ferriprox, the patient should be apprised of the potential hazard to the fetus. Women of reproductive potential should be advised to avoid pregnancy when taking Ferriprox <span class="Italics">[see <a href="#PREGNANCY">Use in Specific Populations (8.1)</a> and <a href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">Nonclinical Toxicology (13.1)</a>]</span>.<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_01C3E348-9F9E-A198-7FB9-ECE336D0993C"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Laboratory Tests</h2>
<p class="First"><span class="Bold">Serum Liver Enzyme Activities</span></p>
<p><span class="Bold"></span>In clinical studies, 7.5% of 642 subjects treated with Ferriprox developed increased ALT values. Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.</p>
<p>Monitor serum ALT values monthly during therapy with Ferriprox, and consider interruption of therapy if there is a persistent increase in the serum transaminase levels.</p>
<p><span class="Bold">Plasma Zinc Concentration</span></p>
<p><span class="Bold"></span>Decreased plasma zinc concentrations have been observed on Ferriprox therapy. Monitor plasma zinc, and supplement in the event of a deficiency.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="_C3CDA94F-1B74-D64E-5688-B5128FE6058F"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">The following adverse reactions are also discussed in other sections of the labeling: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> <span class="Italics">[see <a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943">Warnings and Precautions (5.1)</a>]</span>. Elevated ALT <a href="#_01C3E348-9F9E-A198-7FB9-ECE336D0993C">(5.3)</a>, Decreased plasma zinc concentrations <a href="#_01C3E348-9F9E-A198-7FB9-ECE336D0993C">(5.3)</a>.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Adverse reaction information for Ferriprox represents the pooled data collected from 642 patients who participated in single arm or active-controlled clinical studies.</p>
<p>The most serious adverse reaction reported in clinical trials with Ferriprox was <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> <span class="Italics">[see<a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943"> Warnings and Precautions (5.1)</a>]</span>.</p>
<p>The most common adverse reactions reported during clinical trials were <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">chromaturia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>The table below lists the adverse drug reactions that occurred in at least 1% of patients treated with Ferriprox in clinical trials.</p>
<table frame="void" width="80%">
<caption><span>Table 2: Adverse drug reactions occurring in ≥ 1% of 642 Ferriprox-treated patients</span></caption>
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="2"><span class="Bold">Body System</span></th>
<th rowspan="2" valign="middle"><span class="Bold">% Subjects</span></th>
</tr>
<tr>
<th>  </th>
<th align="left">Preferred Term</th>
</tr>
<tr><td class="Toprule" colspan="3"><span class="Bold">BLOOD AND LYMPHATIC SYSTEM DISORDERS</span></td></tr>
<tr>
<td>  </td>
<td align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center" rowspan="1">6.2</td>
</tr>
<tr>
<td colspan="1"></td>
<td align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></td>
<td align="center" colspan="1">1.7</td>
</tr>
<tr><td colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></span></td></tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" colspan="1" rowspan="1">12.6</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></td>
<td align="center" colspan="1" rowspan="1">10.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" colspan="1" rowspan="1">9.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" colspan="1" rowspan="1">3.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" colspan="1" rowspan="1">2.0</td>
</tr>
<tr><td colspan="3" rowspan="1"><span class="Bold">INVESTIGATIONS</span></td></tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine Aminotransferase</span> increased</td>
<td align="center" colspan="1" rowspan="1">7.5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1">Neutrophil count decreased</td>
<td align="center" colspan="1" rowspan="1">7.3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td align="center" colspan="1" rowspan="1">1.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate Aminotransferase</span> increased</td>
<td align="center" colspan="1" rowspan="1">1.2</td>
</tr>
<tr><td colspan="3" rowspan="1"><span class="Bold">METABOLISM AND NUTRITION DISORDERS</span></td></tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td align="center" colspan="1" rowspan="1">4.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td align="center" colspan="1" rowspan="1">1.1</td>
</tr>
<tr><td colspan="3" rowspan="1"><span class="Bold">MUSCULOSKELETAL AND <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">CONNECTIVE TISSUE DISORDERS</span></span></td></tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" colspan="1" rowspan="1">9.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center" colspan="1" rowspan="1">2.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center" colspan="1" rowspan="1">1.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span></td>
<td align="center" colspan="1" rowspan="1">1.4</td>
</tr>
<tr><td colspan="3" rowspan="1"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></span></td></tr>
<tr>
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" colspan="1" rowspan="1">2.5</td>
</tr>
<tr><td colspan="3" rowspan="1"><span class="Bold"> URINARY DISORDERS</span></td></tr>
<tr class="Last">
<td colspan="1" rowspan="1">  </td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Chromaturia</span></td>
<td align="center" colspan="1" rowspan="1">14.6</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> were the most frequent adverse reactions reported by patients participating in clinical trials and led to the discontinuation of Ferriprox therapy in 1.6% of patients.</p>
<p><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Chromaturia</span> (reddish/brown discoloration of the urine) is a result of the excretion of the iron in the urine.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_19DEE7E9-1F0A-96B7-E2F6-AEF762FA3874"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been reported in patients receiving Ferriprox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.</p>
<p><span class="Bold">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>: <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
<p><span class="Bold">Congenital, familial and genetic disorders</span>: <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>.<span class="Bold"></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span>: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, retinal toxicity.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4106572" conceptname="Hypertrophy of parotid gland">parotid gland enlargement</span>.</p>
<p><span class="Bold">General disorders and administration site conditions</span>: <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, multi-organ failure.</p>
<p><span class="Bold">Hepatobiliary disorders</span><span class="Bold">: </span><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>.<span class="Bold"></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>I<span class="Bold">nfections and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>: cryptococcal cutaneous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, enteroviral <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncle</span>, <span class="product-label-link" type="condition" conceptid="4223947" conceptname="Viral hepatitis, type A">infectious hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>, <span class="product-label-link" type="condition" conceptid="4339469" conceptname="Abscess of external ear">subcutaneous abscess</span>.</p>
<p><span class="Bold">Investigations</span>: blood bilirubin increased, blood creatinine phosphokinase increased.</p>
<p><span class="Bold">Metabolism and nutrition disorders</span>: <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span>: <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="439103" conceptname="Articular cartilage disorder">chondropathy</span>, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">cerebellar syndrome</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial pressure increased</span>, psychomotor skills impaired, pyramidal tract syndrome, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p><span class="Bold">Psychiatric disorders: </span><span class="product-label-link" type="condition" conceptid="4099943" conceptname="Bruxism">bruxism</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, obsessive-compulsive disorder.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>.</p>
<p><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p><span class="Bold">Skin, subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, pruritis, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, Henoch-Schönlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<span class="Bold"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="_ae1f7d66-1500-0844-b15d-fcb050958142"></a><a name="section-7.1"></a><p></p>
<h2> 7.1 Drugs Associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </h2>
<p class="First">Avoid concomitant use of Ferriprox with other drugs known to be associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; however, if this is not possible, closely monitor the absolute neutrophil count <span class="Italics">[see <a href="#_DF7D5737-989A-B85C-5147-FAB6EA015943">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_346c6ccb-ff5e-c161-0c40-9ee9bc836c55"></a><a name="section-7.2"></a><p></p>
<h2> 7.2 UDP-Glucuronosyltransferases (UGTs) </h2>
<p class="First">Deferiprone is primarily eliminated via metabolism to the 3-<span class="Italics">O</span>-glucuronide. <span class="Italics">In vitro </span>studies suggest that UDP glucuronosyltransferase (UGT) 1A6 is primarily responsible for the glucuronidation of deferiprone which can be reduced up to 78% in the presence of the UGT1A6 inhibitor phenylbutazone. However, the clinical significance of coadministration of Ferriprox<a href="#DRUG_INTERACTIONS"></a> with a UGT1A6 inhibitor (e.g. diclofenac, probenecid, or silymarin (milk thistle)) on the systemic exposure of deferiprone has not been determined. Closely monitor patients for adverse reactions that may require downward dose titration or interruption when Ferriprox is concomitantly administered with a UGT1A6 inhibitor.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_1b7d6643-cbc3-d8e9-c5ca-20da7cccc058"></a><a name="section-7.3"></a><p></p>
<h2> 7.3 Polyvalent Cations </h2>
<p class="First">Concurrent use of Ferriprox with foods, mineral supplements, and antacids that contain polyvalent cations has not been studied. However, since deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc), allow at least a 4-hour interval between Ferriprox and other medications (e.g., antacids), or supplements containing these polyvalent cations <span class="Italics">[see <a href="#_e50157d0-ebcc-6cb0-b3f4-6dfd5660a172">Dosage and Administration (2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE_IN_SPECIFIC_POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span><span class="Italics">[see <a href="#_EF6548E5-425A-A1EB-1D85-7714CA42FE86">Warnings and Precautions (5.2)</a>, <a href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">Nonclinical Toxicology (13.1)</a>]</span></p>
<p><span class="Italics">Risk Summary</span></p>
<p>Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman. In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and malformations at doses lower than equivalent human clinical doses. There are no studies in pregnant women, and available human data are limited. If Ferriprox is used during pregnancy or if the patient becomes pregnant while taking Ferriprox, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="Italics">Animal Data</span></p>
<p>Skeletal and soft tissue malformations occurred in offspring of rats and rabbits that received deferiprone orally during organogenesis at the lowest doses tested (25 mg/kg per day in rats; 10 mg/kg per day in rabbits). These doses were equivalent to 3% to 4% of the maximum recommended human dose (MRHD) based on body surface area. No maternal toxicity was evident at these doses.</p>
<p>Embryofetal lethality and maternal toxicity occurred in pregnant rabbits given 100 mg/kg/day deferiprone orally during the period of organogenesis. This dose is equivalent to 32% of the MRHD based on body surface area.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NURSING_MOTHERS"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether deferiprone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from Ferriprox, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PEDIATRIC_USE"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Ferriprox tablets for oral use in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GERIATRIC_USE"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Safety and effectiveness in elderly individuals have not been established. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_10abdfc9-9ebf-46bd-9b43-02fa0ca07c7c"></a><a name="section-8.5"></a><p></p>
<h2>
      8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of Ferriprox. Subjects were categorized into 4 groups based on estimated glomerular filtration rate (eGFR): healthy volunteers (eGFR ≥ 90 mL/min/1.73m<span class="Sup">2</span>), mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 60–89 mL/min/1.73m<span class="Sup">2</span>), moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30–59 mL/min/1.73m<span class="Sup">2</span>), and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 15–29 mL/min/1.73m<span class="Sup">2</span>). Systemic exposure to deferiprone and to its metabolite deferiprone 3-<span class="Italics">O</span>-glucuronide was assessed by the PK parameters C<span class="Sub">max </span>and AUC.</p>
<p>Regardless of the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the majority of the dose of Ferriprox was excreted in the urine over the first 24 hours as deferiprone 3-<span class="Italics">O</span>-glucuronide. No significant effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was seen on systemic exposure to deferiprone. Systemic exposure to the inactive 3-<span class="Italics">O</span>-glucuronide increased with decreasing eGFR. Based on the results of this study, no adjustment of the Ferriprox dosage regimen is required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="_30640f47-25f8-9438-a634-57dad153ba13"></a><a name="section-8.6"></a><p></p>
<h2>
      8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">The influence of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of deferiprone and deferiprone 3-<span class="Italics">O</span>-glucuronide has not been evaluated. Safety and efficacy of Ferriprox have not been evaluated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired hepatic function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of Ferriprox. Subjects were categorized into 3 groups based on the Child-Pugh classification score: healthy volunteers, mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Class A: 5– 6 points), and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Class B: 7– 9 points). Systemic exposure to deferiprone and to its metabolite deferiprone 3-<span class="Italics">O</span>-glucuronide was assessed by the PK parameters C<span class="Sub">max </span>and AUC. The PK of both deferiprone and deferiprone 3-<span class="Italics">O</span>-glucuronide was generally similar in all subjects, regardless of degree of liver impairment. A serious adverse event of acute liver and <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> was seen in one subject with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Based on the results of this study, no adjustment of the Ferriprox dosage regimen is required in patients with mildly or moderately impaired hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> have been reported. There is no specific antidote to Ferriprox <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Neurological disorders such as cerebellar symptoms, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, lateral <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, psychomotor slowdown, hand movements and axial <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span> have been observed in children treated with 2.5 to 3 times the recommended dose for more than one year. The neurological disorders progressively regressed after deferiprone discontinuation.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Ferriprox (deferiprone) tablets contain 500 mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. Deferiprone has the following structural formula:</p>
<p><img alt="ferriprox-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23&amp;name=ferriprox-02.jpg"> </p>
<p>Deferiprone is a white to pinkish-white crystalline powder. It is sparingly soluble in deionized water and has a melting point range of 272°C - 278°C.</p>
<p>Ferriprox tablets are white to off-white, capsule-shaped tablets, and imprinted with “APO? score “500? on one side and plain on the other. The tablets can be broken in half along the score. Each tablet contains 500 mg deferiprone and the following inactive ingredients: Tablet core - microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide; Coating - hydroxypropyl methyl cellulose, polyethylene glycol, titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="MECHANISM_OF_ACTION"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Deferiprone is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has a lower binding affinity for other metals such as copper, aluminum and zinc than for iron.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="PHARMACODYNAMICS"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">No clinical studies were performed to assess the relationship between the dose of Ferriprox and the amount of iron eliminated from the body.</p>
<p><span class="Bold">Cardiac Electrophysiology</span></p>
<p>At a dose 1.5 times the maximum recommended dose, Ferriprox does not prolong the QT interval to any clinically relevant extent.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PHARMACOKINETICS"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract, appearing in the blood within 5 to 10 minutes of oral administration. Peak serum concentrations occur approximately 1 hour after a single dose in fasted healthy subjects and patients, and up to 2 hours after a single dose in the fed state. Administration with food decreased the C<span class="Sub">max</span> of deferiprone by 38% and the AUC by 10%. While a food effect cannot be ruled out, the magnitude of the exposure change does not warrant dose adjustment.</p>
<p>In healthy subjects, the mean maximum concentration (C<span class="Sub">max</span>) of deferiprone in serum was 20 mcg/mL, and the mean total area under the concentration-time curve (AUC) was 53 mcg∙h/mL following oral administration of a 1,500 mg dose of Ferriprox tablets in the fasting state. Dose proportionality over the labeled dosage range of 25 to 33 mg/kg three times per day (75 to 99 mg/kg per day) has not been studied. The elimination half life (t<span class="Sub">1/2</span>) of deferiprone was 1.9 hours. The accumulation of deferiprone and its glucuronide metabolite at the highest approved dosage level of 33 mg/kg three times per day has not been studied. The volume of distribution of deferiprone is 1.6 L/kg in <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> patients, and approximately 1 L/kg in healthy subjects. The plasma protein binding of deferiprone in humans is less than 10%.</p>
<p>In humans, the majority of the deferiprone is metabolized, primarily by UGT1A6. The contribution of extrahepatic (e.g., renal) UGT1A6 is unknown. The major metabolite of deferiprone is the 3-<span class="Italics">O</span>-glucuronide, which lacks iron binding capability. Peak serum concentration of the glucuronide occurs 2 to 4 hours after administration of deferiprone in fasting subjects.</p>
<p>More than 90% of deferiprone is eliminated from plasma within 5 to 6 hours of ingestion. Following oral administration, 75% to 90% is recovered in the urine in the first 24 hours, primarily as metabolite.</p>
<p><span class="Bold">Specific Populations</span></p>
<p>The pharmacokinetics of deferiprone has not been studied in geriatric or pediatric populations, and the influence of race, gender, or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NONCLINICAL_TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been conducted with deferiprone. However, in view of the genotoxicity results, and the findings of mammary gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and mammary gland tumors in rats treated with deferiprone in the 52-week toxicology study, tumor formation in carcinogenicity studies must be regarded as likely.</p>
<p>Deferiprone was positive in a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay in vitro. Deferiprone was clastogenic in an in vitro chromosomal aberration test in mice and in a chromosomal aberration test in Chinese Hamster Ovary cells. Deferiprone given orally or intraperitoneally was clastogenic in a bone marrow micronucleus assay in non-iron-loaded mice. A micronucleus test was also positive when mice predosed with iron dextran were treated with deferiprone. Deferiprone was not mutagenic in the Ames bacterial reverse mutation test.</p>
<p>A fertility and early embryonic development study of deferiprone was conducted in rats. Sperm counts, motility and morphology were unaffected by treatment with deferiprone. There were no effects observed on male or female fertility or reproductive function at the highest dose which was 25% of the MRHD based on body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a prospective, planned, pooled analysis of patients from several studies, the efficacy of Ferriprox was assessed in transfusion-dependent <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> patients in whom previous iron chelation therapy had failed or was considered inadequate due to poor tolerance. The main criterion for chelation failure was serum ferritin &gt; 2,500 mcg/L before treatment with Ferriprox. Ferriprox therapy (35-99 mg/kg/day) was considered successful in individual patients who experienced a ≥ 20% decline in serum ferritin within one year of starting therapy.</p>
<p>Data from a total of 236 patients were analyzed. Of the 224 patients with <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> who received deferiprone monotherapy and were eligible for serum ferritin analysis, 105 (47%) were male and 119 (53%) were female. The mean age of these patients was 18.2 years.</p>
<p>For the patients in the analysis, the endpoint of at least a 20% reduction in serum ferritin was met in 50% (of 236 subjects), with a 95% confidence interval of 43% to 57%.</p>
<p>A small number of patients with <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> and iron overload were assessed by measuring the change in the number of milliseconds (ms) in the cardiac MRI T2* value before and after treatment with deferiprone for one year. There was an increase in cardiac MRI T2* from a mean at baseline of 11.8 ± 4.9 ms to a mean of 15.1 ± 7.0 ms after approximately one year of treatment. The clinical significance of this observation is not known.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">FERRIPROX<span class="Sup">®</span> (deferiprone) tablets are white to off-white, capsule-shaped tablets, film-coated, and have a functional score imprinted with “APO? score “500? on one side and are plain on the other. They are provided in a 100 count HDPE bottle with a child-resistant cap.</p>
<p>500 mg film-coated tablets, 100 tablets NDC 52609-0006-1</p>
<p>Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [see USP Controlled Room Temperature].</p>
<p>Keep Ferriprox out of the reach and sight of children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INFORMATION_FOR_PATIENTS"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling (Medication Guide)</span></p>
<ul>
<li>Inform patients of the risks of developing <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and instruct them to immediately interrupt therapy and report to their physician if they experience any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> or flu-like symptoms.</li>
<li>Advise patients that the amount of Ferriprox prescribed is based on body weight and on the therapeutic goal (reduction or stabilization of the body iron load).</li>
<li>Advise patients to take the first dose of Ferriprox in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking Ferriprox with meals may reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. If a dose of this medicine has been missed, take as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not catch-up or double doses.</li>
<li>Advise patients to contact their physician in the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</li>
<li>Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect of Ferriprox, and it is not harmful.</li>
<li>Counsel women of reproductive potential to avoid pregnancy while taking Ferriprox. Advise patients to immediately notify their physician if they become pregnant, or if they plan to become pregnant during therapy.</li>
<li>Inform patients that they should not breast feed while taking Ferriprox.</li>
</ul>
<p>Distributed by ApoPharma USA, Inc., Rockville, MD, United States of America, 20850. Manufactured by Apotex Inc., Toronto, Ontario, Canada, M9L 1T9</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_6d48ee59-a1cd-59c6-0625-9f60d1f3f73e"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">MEDICATION GUIDE</span></h1>
<p class="First"><span class="Bold">FERRIPROX<span class="Sup">®</span> (Feh’ ri prox)</span></p>
<p><span class="Bold"></span><span class="Bold">(deferiprone)</span></p>
<p><span class="Bold"> tablets </span></p>
<p>Read this Medication Guide before you start taking FERRIPROX and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about FERRIPROX?</span></p>
<p>FERRIPROX can cause serious side effects, including a very low white blood cell count in your blood.  One type of white blood cell that is important for fighting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is called a neutrophil. If your neutrophil count is low (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), you may be at risk of developing a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> is common with FERRIPROX and can become severe in some people. Severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is known as <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. If you develop <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, you will be at risk of developing serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Your healthcare provider should do a blood test before you start FERRIPROX and weekly during treatment to check your neutrophil count. If you develop <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, your healthcare provider should check your blood counts every day until your white blood cell count improves.  <span class="Bold"></span></p>
<p>Stop taking FERRIPROX and get medical help right away if you develop any of these symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> or mouth sores</li>
<li>flu-like symptoms</li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and severe <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span></li>
</ul>
<p>See <span class="Bold">“What are the possible side effects of FERRIPROX??</span> for more information about side effects.</p>
<p><span class="Bold">What is FERRIPROX?</span></p>
<p>FERRIPROX is a prescription medicine used to treat people with <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> syndromes who have <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> from blood transfusions, when current iron removal (chelation) therapy does not work well enough.</p>
<p>It is not known if FERRIPROX tablets are safe and effective:</p>
<ul>
<li>to treat <span class="product-label-link" type="condition" conceptid="4246084" conceptname="Iron overload">iron overload</span> due to blood transfusions in people with any other type of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> that is long lasting (chronic) </li>
<li>in children</li>
<li>in people with severe liver problems</li>
</ul>
<p><span class="Bold">Who should not take FERRIPROX?</span></p>
<p><span class="Bold"></span><span class="Bold">Do not take FERRIPROX if yo</span><span class="Bold">u are allergic to deferiprone or any of the ingredients in FERRIPROX. </span>See the end of this Medication Guide for a complete list of ingredients in FERRIPROX.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking FERRIPROX?</span></p>
<p><span class="Bold"></span><span class="Bold">Before you take FERRIPROX, tell your healthcare provider if you:</span></p>
<ul>
<li>have liver problems</li>
<li>have any other medical conditions.</li>
<li>are pregnant or plan to become pregnant. FERRIPROX can harm your unborn baby. You should avoid becoming pregnant while taking FERRIPROX. Tell your healthcare provider right away if you become pregnant or plan to become pregnant while taking FERRIPROX.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if FERRIPROX passes into your breast milk. You and your healthcare provider should decide if you will take FERRIPROX or breastfeed.  You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins and herbal supplements.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul>
<li>other medicines that can cause a lowering of your neutrophil count</li>
<li>antacids or mineral supplements that contain: iron, aluminum, and zinc.  <span class="Bold">Allow at least 4 hours between taking FERRIPROX and any of these products.</span>
</li>
</ul>
<p>Ask your healthcare provider or pharmacist if your medicine is one that is listed above.</p>
<p>Know the medicines you take.  Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.<span class="Bold"></span></p>
<p><span class="Bold"></span><span class="Bold">How should I take FERRIPROX?</span></p>
<ul>
<li>Take FERRIPROX exactly as prescribed by your healthcare provider. Do not change your dose of FERRIPROX unless your healthcare provider tells you to.</li>
<li>Your healthcare provider will tell you how many FERRIPROX tablets to take.</li>
<li>FERRIPROX is taken 3 times each day.  Take your first dose in the morning, the second dose at mid-day, and third dose in the evening.</li>
<li>You can take FERRIPROX with or without food.</li>
<li>Taking FERRIPROX with meals may help reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </li>
<li>If you take too much FERRIPROX, call your healthcare provider.</li>
<li>If you do miss a dose take it as soon as you remember.  If it is almost time for your next dose, skip the missed dose and then continue with your regular schedule.  Do not try to catch-up or take 2 doses at the same time to make up for a missed dose.</li>
</ul>
<p><span class="Bold">What are the possible side effects of FERRIPROX?</span></p>
<p><span class="Bold"></span>FERRIPROX can cause serious side effects, including:</p>
<ul>
<li>
<span class="Bold">See “What is the most important information I should know about FERRIPROX?</span>?</li>
<li>
<span class="Bold">Increased liver enzyme levels in your blood.</span> Your healthcare provider should do monthly blood test to check your liver function during treatment with FERRIPROX.</li>
</ul>
<p>The most common side effects of FERRIPROX include:</p>
<ul>
<li>reddish-brown colored urine.  This is not harmful and is expected when you are taking FERRIPROX. </li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>stomach-area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li>low neutrophil count. See “What is the most important information I should know about FERRIPROX??</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of FERRIPROX. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800-FDA-1088.</p>
<p><span class="Bold">How should I store FERRIPROX?</span></p>
<ul><li>Store FERRIPROX at room temperature between 68<span class="Sup">○</span>F to 77<span class="Sup">○</span>F (20<span class="Sup">○</span>C to 25<span class="Sup">○</span>C).</li></ul>
<p><span class="Bold">Keep FERRIPROX and all medicines out of the reach of children.</span><span class="Bold"></span></p>
<p><span class="Bold"></span><span class="Bold">General information about the safe and effective use of FERRIPROX.</span></p>
<p><span class="Bold"></span>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FERRIPROX for a condition for which it was not prescribed. Do not give FERRIPROX to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about FERRIPROX. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about FERRIPROX that is written for health professionals.</p>
<p>For more information call 1-866-949-0995.</p>
<p><span class="Bold">What are the ingredients in FERRIPROX?</span></p>
<p><span class="Bold">Active ingredients: </span>deferiprone </p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p>   Tablet core: microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide.</p>
<p>   Coating: hydroxypropyl methyl cellulose, polyethylene glycol, titanium dioxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Distributed by:</span></p>
<p> ApoPharma USA, Inc., Rockville, MD, United States of America, 20850.</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Apotex Inc., Toronto, Ontario, Canada, M9L 1T9.</p>
<p>Revised February 2015</p>
<p>Trademark disclaimers.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_1be2a39a-4754-0f52-c221-a40774662c8c"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First"><span class="Bold">ApoPharma USA, Inc.</span> NDC 52609-0006-1</p>
<p><span class="Bold">Ferriprox tablets</span></p>
<p>500 mg</p>
<p><span class="Bold">Rx only</span></p>
<p>100 Tablets</p>
<p><img alt="ferriprox-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23&amp;name=ferriprox-01.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FERRIPROX 		
					</strong><br><span class="contentTableReg">deferiprone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52609-0006</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEFERIPRONE</strong> (DEFERIPRONE) </td>
<td class="formItem">DEFERIPRONE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52609-0006-1</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021825</td>
<td class="formItem">11/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ApoPharma USA, Inc.
							(962810821)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Apotex Inc. (209429182)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>abd64643-d7c2-4db0-bd2d-16f4350d8fa9</div>
<div>Set id: dc8cbc3d-026c-0db5-42e8-8e93d374dd23</div>
<div>Version: 3</div>
<div>Effective Time: 20150224</div>
</div>
</div> <div class="DistributorName">ApoPharma USA, Inc.</div></p>
</body></html>
